The Maryland-based company is working with partners to address significant unmet medical needs in areas such as HIV, hepatitis B and C virus, influenza, and other respiratory pathogens, as well as herpes viruses and other emerging or re-emerging infections. ImQuest Life Sciences has a portfolio of therapeutic drugs that inhibit these organisms through novel targets and means of intervention.